Background: Clinically derived bowel assessment tools are utilised within research for the identification of AI within the pregnant and postnatal population (1). The benefits of direct questioning utilising bowel assessment tools can improve the identification of AI in this cohort (2). There is minimal research that explores the reasons for discordance between different assessment tools from the afflicted person's perspective. The aim of this research was to explore women's experiences in disclosing symptoms of AI when completing three-bowel assessment tools, bowel-screening tool (BSQ), St Marks Vaizey score and Wexner score.
tioning utilising bowel assessment tools can improve the identification of AI in this cohort (2) . There is minimal research that explores the reasons for discordance between different assessment tools from the afflicted person's perspective. The aim of this research was to explore women's experiences in disclosing symptoms of AI when completing three-bowel assessment tools, bowel-screening tool (BSQ), St Marks Vaizey score and Wexner score.
Methods: A phenomenological qualitative research study was undertaken in a large tertiary hospital within South Australia July 2016 to May 2017. Purposeful recruitment of pregnant women in the first trimester of pregnancy was undertaken. Women participated in qualitative semistructured interviews. Ethics was received through two ethics committees.
Results: Women (n = 16, 22-42 years) with a history of AI following the first birth (n = 12) or the second (n = 4) provided differing responses between the three assessment tools. The Vaizey and Wexner scores were more difficult to complete due to clinical language and participants level of comprehension. Women identified major themes as barriers for disclosing AI, which included social expectations, trusted space and confusion.
Conclusion: Many factors affect disclosure including social taboos, stigma, and current beliefs regarding birth trauma and assessment tools used to identify AI. To improve disclosure of AI, assessment tools need to be easy to understand and facilitate discussion on the topic. Early identification of AI improves health outcomes. 
IDENTIFYING ANAL INCONTINENCE IN
. The aim of this prospective study was to utilise a specifically designed bowel-screening questionnaire (BSQ) to identify AI in women of reproductive age in an antenatal and community setting.
Methods: July 2017-April 2018 women attending an antenatal clinic in a large tertiary hospital and parous women from a community health clinic in the northern suburbs of Adelaide, South Australia were recruited and completed the BSQ. Preliminary results have utilised SPPS for statistical analysis and findings are reported as number and percentages. Ethics was received through two ethics committees.
Results: 68.4% of antenatal women and 51% of community women reported a history of AI. 22% of antenatal and 10% of community group reported current symptoms. Symptoms were often variable with flatus and rectal urgency predominant symptoms. There was an association with AI and 1st /2nd delivery, forceps delivery, episiotomy and OASIS for both groups.
Conclusion: There is an increased prevalence of historical AI in this cohort. Whilst current prevalence of AI is lower, the predominance of precursors for worsening function such as rectal urgency and flatus identifies the need to actively screen for AI, to improve identification and subsequent management of this group. Background: Low-dose aspirin (LDA) has been shown to reduce the risk of pre-eclampsia (PE), low birthweight (LBW) and preterm birth (PTB) whilst its effect on adverse perinatal outcomes remains unclear.
THE IMPACT OF LOW DOSE ASPIRIN ON ADVERSE
Objective: Perform a meta-analysis and meta-regression of randomised controlled trials evaluating the impact of LDA on perinatal outcomes independent of its effect on PE, LBW and PTB.
Methods: Studies published between 1994 and November 2018 were identified through a detailed literature search including EMBASE, PUBMED and CENTRAL. Risk ratios (RR) and 95% confidence intervals (CI) were calculated and pooled for analysis. Meta-regression assessed the effect of LDA upon perinatal outcomes independent of the development of PE, LBW or PTB.
Results: 31 studies containing 30 974 participants were included. LDA was associated with a significant reduction in risk of 5-min Apgar score < 7 (RR 0.75 95%CI 0.58-0.96, p < 0.05), admission to the neonatal intensive care unit (NICU) if <100 mg was administered (RR 0.92, 95%CI 0.86-0.99, p < 0.05), periventricular haemorrhage (PVH) if treatment commenced after 16 weeks gestation (RR 0.64, 95%CI 0.42-0.96, p < 0.05) and perinatal death (PND) (RR 0.86, p < 0.05) . Meta-regression demonstrated the effect upon PND was independent of any reduction in PE and LBW but not PTB. After adjusting for these confounders, the beneficial effect of LDA upon 5-min Apgar score < 7 failed to persist.
Conclusions: LDA improves some perinatal outcomes including NICU admission, 5-min Apgar score < 7, PVH and PND. Furthermore, the improvement in risk of PND is independent of any reduction in PE or LBW.
